You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
NervGen Pharma Corp. filed an Amendment No. 1 to restate its interim financial statements for the three and six months ended June 30, 2026 and 2025 due to non-cash valuation errors in stock options and warrant derivative liabilities.
NervGen Pharma Corp. filed an amended and restated MD&A restating 2025 and 2024 financials due to a material weakness in internal controls. During 2025, NVG-291 met its primary endpoint in the CONNECT SCI Study, and the company completed a US$10,049,915 private placement.
NervGen Pharma Corp. said on September 25, 2026 that affected financial statements should no longer be relied upon due to non-cash valuation errors involving stock options and warrant liabilities; the restatement does not affect cash position, cash flow or liquidity.
NervGen Pharma Corp. appointed KPMG LLP (US) as auditor effective September 15, 2026 after KPMG LLP (Canada) resigned at the company’s request; the appointment runs until the close of the next annual meeting of shareholders.
